/SYNACT.ST
SYNACT.ST Stock - SynAct Pharma AB
Healthcare|BiotechnologySTO
$23.80+7.94%
+$1.75 (+7.94%) • Dec 23
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $26.18
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SYNACT.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$23.56 – $24.04
TARGET (TP)$27.37
STOP LOSS$21.90
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.14
52W High$25.30
52W Low$8.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-617,000 | $-778,000 | $-1,064,000 | $-88,000 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-89,980,000 | $-224,496,000 | $-105,705,000 | $-76,699,000 | $-31,285,000 |
| Net Income | $-82,401,000 | $-215,810,000 | $-99,205,000 | $-69,304,000 | $-26,551,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.08 | $-6.64 | $-3.60 | $-2.67 | $-1.23 |
Company Overview
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SYNACT.STBeat Rate
0%
Last 7 quarters
Avg Surprise
-98.5%
EPS vs Estimate
Beats / Misses
0/7
Last 12 quarters
Latest EPS
$-0.51
Q2 2025
EPS Surprise History
Q3 23
No data
Q4 23
-1.1%
$-1.00vs$-0.99
Q1 24
-242.7%
$-2.58vs$-0.75
Q2 24
-101.9%
$-0.70vs$-0.35
Q2 24
-127.1%
$-0.47vs$-0.21
Q3 24
-138.4%
$-0.50vs$-0.21
Q1 25
-16.9%
$-0.44vs$-0.38
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 30, 2025 | — | — | — | — |
Q2 2025 | May 27, 2025 | — | $-0.51 | — | — |
Q1 2025 | Feb 18, 2025 | $-0.38 | $-0.44 | -16.9% | ✗ MISS |
Q3 2024 | Sep 30, 2024 | $-0.21 | $-0.50 | -138.4% | ✗ MISS |
Q2 2024 | Jun 29, 2024 | $-0.21 | $-0.47 | -127.1% | ✗ MISS |
Q2 2024 | Apr 24, 2024 | $-0.35 | $-0.70 | -101.9% | ✗ MISS |
Q1 2024 | Feb 23, 2024 | $-0.75 | $-2.58 | -242.7% | ✗ MISS |
Q4 2023 | Oct 24, 2023 | $-0.99 | $-1.00 | -1.1% | ✗ MISS |
Q3 2023 | Aug 4, 2023 | — | $-1.37 | — | — |
Q2 2023 | May 5, 2023 | — | $-1.59 | — | — |
Q1 2023 | Feb 17, 2023 | — | $-1.06 | — | — |
Q4 2022 | Nov 4, 2022 | — | $-0.84 | — | — |
Q3 2022 | Aug 5, 2022 | — | $-0.91 | — | — |
Q2 2022 | May 30, 2022 | — | $-0.77 | — | — |
Q1 2022 | Feb 11, 2022 | $-0.62 | $-1.00 | -61.4% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-0.70 | — | — |
Q3 2021 | Aug 27, 2021 | — | $-0.51 | — | — |
Q2 2021 | May 5, 2021 | — | $-0.46 | — | — |
Q1 2021 | Feb 12, 2021 | — | $-0.36 | — | — |
Q4 2020 | Nov 13, 2020 | — | $-0.31 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SYNACT.ST
What is SYNACT.ST's current stock price?
SynAct Pharma AB (SYNACT.ST) is currently trading at $23.80 per share. The stock has moved +7.94% today.
What is the analyst price target for SYNACT.ST?
No analyst price targets are currently available for this stock.
What sector is SynAct Pharma AB in?
SynAct Pharma AB operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is SYNACT.ST's market cap?
SynAct Pharma AB has a market capitalization of $1.27 billion, making it a small-cap company.
Does SYNACT.ST pay dividends?
No, SynAct Pharma AB does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCANTA.ST
Cantargia AB (publ)
$4.09
Mkt Cap: $1.0B
CRAD-B.ST
C-Rad AB (publ)
$31.85
Mkt Cap: $1.0B
DMYD-B.ST
Diamyd Medical AB (publ)
$10.08
Mkt Cap: $1.4B
GENO.ST
Genovis AB (publ.)
$21.20
Mkt Cap: $1.4B
IBT-B.ST
Infant Bacterial Therapeutics AB (publ)
$49.00
Mkt Cap: $0.6B
ITECH.ST
I-Tech AB
$52.80
Mkt Cap: $0.6B
ONCO.ST
Oncopeptides AB (publ)
$4.57
Mkt Cap: $1.0B
ORX.ST
Orexo AB (publ)
$27.30
Mkt Cap: $0.9B
SEDANA.ST
Sedana Medical AB (publ)
$9.92
Mkt Cap: $1.0B
XSPRAY.ST
Xspray Pharma AB (publ)
$31.20
Mkt Cap: $1.1B
Explore stocks similar to SYNACT.ST for comparison